menuMenu Our Work in Immuno-Oncology Global cancer cases continue to rise. The fight against cancer is personal – not only for patients and their loved ones but also for those focused on treating cancer and developing new treatments. 5 Million In 2018, it is estimated that approximately 18 million people worldwide were diagnosed and about 9 million people died from cancer.1 9 Million By 2040, new cancer cases worldwide are predicted to almost 30 million.2 “New therapies that save and improve lives are invaluable for patients and their families. We as a Market Access Team, are proudly committed to providing all appropriate patients in Belgium with innovative treatment options as rapidly as possible.” Eline Darquennes, Market Access Lead MSD Belgium & Luxembourg Our Inspiration We believe that one day cancer will be curable. We work with all involved public and private institutions responsible for the treatment and care of patients with cancer to help those affected and their families. Our progress in changing the outcomes of cancer would not be possible without: ...the participation of patients in clinical trials. ...the support and involvement of the physicians who believe in the importance of advancing the care for patients through innovative clinical trials ...the patient advocacy community who helps support people with cancer through their journeys Cancer and the role of the immune system The past In the 1950s, researchers proposed that the immune system patrols the body to detect and destroy tumor cells. Scientists and researchers had previously focused on cancer cells and treating cancer as a genetic disease. The Present Now the focus is shifting to the microenvironment in which cancer grows, including the immune system – an approach called immuno-oncology. The Future Immuno-oncology has the potential to change the way cancer is treated and how patients can benefit from it. Anti-PD1 * therapy (French) Anti-PD1 * therapy (Dutch) The immune system - a key in the fight against cancer To the infographic Immuno-oncological research could lead to significant progress in the treatment of the world's ten most common cancers. (Newly diagnosed cases worldwide in 20183) LUNG CANCER 2.093.876 BREAST CANCER 2.088.849 COLORECTAL CARCINOMA 1.800.977 PROSTATE CANCER 1.276.106 STOMACH CANCER 1.033.106 LIVER CANCER 841.080 ESOPHAGEAL CARCINOMA 572.034 CERVICAL CANCER 569.847 THYROID CANCER 567.233 BLADDER CANCER 549.393 We strive to provide hope to people with cancer We invest in the development of innovative oncological drugs to provide hope to people with cancer. With a focus on immuno-oncology, MSD has one of the largest and fastest growing clinical research programs in the world. MSD is one of the leading companies in research on vaccines, such as cervical cancer. The ongoing clinical study program in the field of immuno-oncology in Belgium includes 34 clinical studies in various cancers (as of 04/2019). References * Anti-Programmed Death-1 1 http://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf, viewed 14.11.2019 2 http://gco.iarc.fr/tomorrow/home, viewed 14.11.2019 3 http://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf, viewed 14.11.2019 © MSD Belgium BE-NON-00320. Date of last revision: 12/2019 Legal Notice Terms of Use Data Protection Cookie Preferences This Site Uses Cookies and Your Privacy Choice Is Important to Us We suggest you choose Customize my Settings to make your individualized choices. Accept Cookies means that you are choosing to accept third-party Cookies and that you understand this choice. See our Privacy Policy Reject Cookies Accept Cookies Customize my Settings